Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04470388
Other study ID # EDP 514-002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 9, 2020
Est. completion date August 30, 2021

Study information

Verified date January 2022
Source Enanta Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled study in viremic chronic hepatitis B subjects, assessing the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days treatment with EDP-514.


Description:

The study assesses multiple ascending doses of EDP-514 compared to placebo for 28 days in viremic chronic CHB-infected subjects not currently on treatment. Each cohort will enroll a total of 8 subjects who will be randomized to receive EDP-514 or placebo.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date August 30, 2021
Est. primary completion date August 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - An informed consent document signed and dated by the subject. - Healthy male and female subjects of any ethnic origin between the ages of 18 and 70 years, inclusive - HBV DNA levels: - For subjects who are HBeAg positive at Screening, a Screening HBV DNA level in serum/plasma that is =20,000 IU/ml, or - For subjects who are HBeAg negative at Screening, a Screening HBV DNA level in serum/plasma that is =2,000 IU/mL, and - For all subjects, no HBV DNA serum/plasma test values <1,000 IU/ml over the previous 12 months (using an approved test) - CHB subjects must not have been on prescribed anti-HBV treatment for at least 12 months prior to Screening Exclusion Criteria: - A documented prior diagnosis of cirrhosis - Pregnant or nursing females - Coinfection with human immunodeficiency virus (HIV), HCV, HDV, HAV, or HEV - Chronic liver disease of a non-HBV etiology; coexisting liver or biliary diseases

Study Design


Intervention

Drug:
EDP-514
Oral Capsule
Placebo
Placebo to match EDP-514

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong
Taiwan Changhua Christian Hospital Changhua
Taiwan Chia-Yi Christian Hospital Chiayi
Taiwan E-Da Hospital/E-DA Cancer Hospital Kaohsiung
Taiwan Kaohsiung Chang Gung Memorial Hospital Kaohsiung
Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung
Taiwan China Medical University Hospital Taichung
Taiwan National Cheng Kung University Hospital Tainan
Taiwan National Taiwan University Hospital Taipei
Taiwan Chang Gung Medical Foundation, Chang Gung Memorial Hospital, Linkou Branch Taoyuan

Sponsors (2)

Lead Sponsor Collaborator
Enanta Pharmaceuticals Pharmaceutical Research Associates

Countries where clinical trial is conducted

Hong Kong,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety measured by adverse events Up to 84 Days in HBV MAD Cohorts
Secondary Cmax of EDP-514 Up to 28 Days in HBV MAD Cohorts
Secondary AUC of EDP-514 Up to 28 Days in HBV MAD Cohorts
Secondary Change from baseline in HBV DNA Viral Load Assay through Day 28 in HBV MAD Cohorts
See also
  Status Clinical Trial Phase
Completed NCT05019040 - Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients Phase 1/Phase 2
Completed NCT01943799 - Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B Phase 2
Recruiting NCT05792761 - A Study on Antiviral Treatment of Chronic Hepatitis B in Children N/A
Completed NCT05468060 - Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects Phase 1
Completed NCT04008004 - A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) Phase 1
Active, not recruiting NCT05734807 - A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia Phase 2
Completed NCT06029634 - Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
Completed NCT04147208 - Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection Phase 2
Completed NCT03909191 - Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage
Completed NCT03664518 - to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection Phase 2
Completed NCT05542979 - A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection Phase 1
Active, not recruiting NCT03903796 - Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection Phase 3
Completed NCT05851261 - Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects Phase 1